Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[From external to implantable insulin pump, can we close the loop?].

E Renard1, G Costalat, J Bringer

  • 1Service des Maladies Endocriniennes, Hôpital Lapeyronie, 34295 Montpellier Cedex 5, France. e-renard@chu-montpellier.fr

Diabetes & Metabolism
|November 21, 2002
PubMed
Summary

An artificial beta cell system for diabetes management demonstrated feasibility in trials. This closed-loop insulin delivery, combining implantable sensors and pumps, offers improved glucose control for type 1 diabetic patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of eating disorders and/or insulin omission with impaired glycaemic control in persons living with type 1 diabetes: cross-sectional analysis of the French SFDT1 study.

BMJ open·2026
Same author

Practical implementation of automated insulin delivery systems in 2025: A French position statement update.

Diabetes & metabolism·2025
Same author

Megalencephaly secondary to a novel germline missense variant p.Asp322Tyr in AKT3 associated with growth hormone deficiency and central hypothyroidism: A case report.

American journal of medical genetics. Part A·2024
Same author

High incidence of skin reactions secondary to the use of adhesives in glucose sensors or insulin pumps for the treatment of children with type 1 diabetes.

Diabetes research and clinical practice·2023
Same author

Maternal opioid addiction: A potential cause of elevated 17-OH progesterone in neonatal screening.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
Same author

[After the COVID crisis, what solutions for the future nursing home?]

Bulletin de l'Academie nationale de medecine·2022

Area of Science:

  • Biomedical Engineering
  • Endocrinology
  • Medical Devices

Context:

  • The development of artificial beta cell systems aims to restore physiological insulin function in diabetic patients.
  • Advances in micro-electronics, biomaterials, and insulin solutions have enabled sophisticated insulin delivery systems.
  • Implantable insulin pumps offer a physiological and efficient mode of insulin therapy.

Purpose:

  • To evaluate the feasibility of a closed-loop artificial beta cell system for automated insulin delivery.
  • To assess glucose control in type 1 diabetic patients using an implantable sensor and pump system.
  • To investigate the potential of restoring physiological insulin secretion through an implanted artificial pancreas.

Summary:

  • A prototype implantable artificial beta cell, the Long Term Sensor System, was developed by combining implantable insulin pumps and intravascular glucose sensors.

Related Experiment Videos

  • Clinical trials demonstrated the feasibility of closed-loop insulin delivery for 48-hour periods in type 1 diabetic patients.
  • This system achieved glucose control closer to physiological levels compared to open-loop systems.

    • Impact:

    • Successful trials suggest the potential restoration of natural insulin function in diabetic individuals.
    • The artificial beta cell system represents a significant step towards advanced diabetes management.
    • Further algorithm refinement could enhance automated insulin delivery and patient outcomes.